Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by…
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis…
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or…
BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a…
July 28, 2025 12:04 ET | Source: Floe Health San Francisco, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Floe Health,…
July 10, 2025 16:30 ET | Source: NKGen Biotech, Inc. SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen…
July 01, 2025 09:00 ET | Source: Inmagene Biopharmaceuticals The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007…
Accelmed $20 Million Investment with 3E Bioventures Capital Funding of $3 Million to Drive Innovation, Clinical Expansion, and Global Market…
New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and delivers increased efficiencies for clinical trials SINGAPORE, June…